Introduction
Structural hepatic changes are a recognized complication after palliative Fontan surgery of patients with severe congenital heart disease. 1, 2 The Fontan procedure establishes a unique haemodynamic physiology, resulting from a direct conduit between caval veins and pulmonary arteries. 3, 4 As a consequence, caval pressure rises resulting in elevated hepatic afterload, liver congestion, and increased risk of liver fibrosis. 5 Multidisciplinary consensus recommends hepatological evaluation of patients for Fontan-associated liver disease (FALD), however, specific guidelines how to commence screening are lacking. 6 Since liver fibrosis is mostly asymptomatic, clinical history, and physical examination are of limited value. As in many other chronic liver diseases routine liver biochemistry is inaccurate to quantify Fontan-associated liver fibrosis. [7] [8] [9] Several non-invasive tools, such as transient elastography and fibrosis biomarkers have gained traction to diagnose and quantify fibrosis but have only been evaluated to a limited extent in this population. [10] [11] [12] A liver biopsy is considered to be the gold standard for staging of hepatic fibrosis and is used as the reference standard method in evaluations of biomarkers and non-invasive markers of liver fibrosis. However, biopsies are invasive and carry a certain risk of complications, in particular bleeding. 13 The exact bleeding risk is unknown, but could be high in the Fontan population in view of the frequent use of anticoagulants. 14 There are a number of studies that have evaluated the extent of liver disease in this population, but they are hampered by retrospective design, selection bias, or the absence of histology as reference standard. [10] [11] [12] [15] [16] [17] [18] [19] [20] [21] [22] It is unclear which investigations contribute to true prognostic information that changes clinical management and outcomes. The aims of this study were (i) to assess the clinical spectrum of FALD including signs of portal hypertension and hepatic nodules in asymptomatic patients with a Fontan physiology and (ii) to examine the usefulness of serum and image-based fibrosis markers to assess fibrosis, in comparison to liver biopsy as the reference standard.
Methods

Study population
All consecutive patients (18 years or older) with a Fontan physiology, monitored at the Congenital Cardiology Department of the Radboud University Medical Centre were referred to the hepatology department for a prospective screening programme for liver disease. Inclusion took place from November 2015 to September 2017. The screening protocol consisted of routine biochemistry testing, VO 2 max exercise test, cardiac and liver ultrasound, transient elastography, advanced imaging of the liver with magnetic resonance imaging (MRI) or computed tomography (CT) scan, and liver biopsy (See take home figure). Patients were required to consent for the individual procedures. All procedures were performed on the same day, whereas the liver biopsy procedure and advanced imaging were performed within a range of 3 months. Data from clinical evaluations was collected through chart review. The study was approved by the institutional review board of the Radboud university medical centre (no. 2015-2132).
Clinical evaluation
All patients were simultaneously clinically evaluated at the Departments of Hepatology and Cardiology. Patients were evaluated for risk factors for liver disease such as alcohol and drug use. Physical examination included haemodynamic parameters and signs of Fontan failure or liver disease such as peripheral oedema, ascites, spider naevi, palmar erythema, and jaundice. Patients underwent cardiac ultrasonography, visually assessing global ventricle function, and a VO 2 max test. 23, 24 Liver biopsy and histological assessment Ultrasound guided percutaneous liver biopsy (16G, true-cut or suction biopsy) was performed under conscious sedation by experienced hepatologists (E.T.T.L.T, J.P.H.D.). Liver tissue slides were stained with haematoxylin-eosin, elastica-Van Gieson, and picrosirius red. Slides were evaluated independently by two liver pathologists experienced in vascular liver disease (C.M.B, T.J.K.). Adequate biopsy samples were defined as length > _2 cm and the presence of > _11 portal tracts. Three fibrosis scores, previously reported to assess Fontan-associated liver fibrosis, were assessed: Gross architectural distortion score, 17 scoring overall fibrosis distribution, and architectural changes (ranging 0-4); a four component score, 18 scoring portal fibrosis (0-4), sinusoidal fibrosis (0-4), sinusoidal dilation (0-3), portal inflammation (0-3); and the congestive heart failure fibrosis score (CHFS; 0-4). 25 See Supplementary material online, Methods for exact description of scores.
To obtain a comprehensive overview of total amount of fibrosis present, the percentage of total tissue area occupied by collagen (picrosirius red stain) or so-called collagen proportionate area (CPA) was calculated, as described before. 26 Steatosis was assessed with NAFLD activity score (0-3). 27 
Laboratory evaluation
Laboratory testing included routine liver biochemistry [alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphotase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, and liver function tests (INR or prothrombin time, platelets, and albumin)]. Hepatitis B and C serology was tested. A commercial panel of direct fibrosis markers was assessed (Enhanced Liver Fibrosis Test V R , Siemens, the Netherlands) consisting of hyaluronic acid, PIIINP, and TIMP-1. The score has a cut-off of > _7.7 for the presence of fibrosis. 28 Furthermore the APRI, an indirect fibrosis score was calculated from AST and platelets. 29 Von
Willebrand factor (vWf) and VITRO score (VWF/platelet ratio), as surrogate markers for portal hypertension, were measured. 30, 31 MELD-XI score (developed to assess end-stage liver disease in patients on anticoagulants by excluding INR) was calculated. 32 
Liver ultrasonography and transient elastography
Dedicated liver ultrasonography (Hitachi Preius TM) was performed, and evaluation focused on aspect, pattern of parenchyma and liver surface, assessment of focal lesions, presence of ascites, and spleen size. Standardized Doppler flow measurements were performed on inferior caval vein (diameter, respiratory variability), hepatic veins (diameter, flow pattern), portal vein (flow direction and flow velocity), and hepatic artery (peak systolic flow velocity, end diastolic flow velocity, and resistance index). Liver stiffness (in kPa) was measured by transient elastography with Fibroscan 502 V R , assessing the median of > _10 measurements with an interquartile range/median < _30%.
Spleen diameter (mm) and platelet count were incorporated in the platelet/spleen ratio, with a proposed cut-off of <909 for identification of patients at risk for presence of clinically relevant portal hypertension. 33 .
Advanced imaging
A contrast-enhanced MRI was performed (Dotarem V R ; gadoterate meglumine contrast, Siemens, 3 T), or in case this was not possible a multiphase liver CT-scan (iodinated contrast, Toshiba, slide thickness 5 mm). For clinical CT and MRI protocols, see Supplementary material online, Methods. Liver radiologists and a specialized vascular liver radiologist (M.R.) assessed and semi-quantitatively scored imaging characteristics of fibrosis and portal hypertension: liver nodularity and dysmorphy, size of liver segment 1 and 4, ascites, splenomegaly, and varices. Ascites was defined as the presence of any amount of free fluid in the peritoneal cavity. Splenomegaly was defined as a spleen diameter >12 cm. Spleen diameter was calculated as the largest spleen bipolar diameter at the splenic hilum. Varices were defined as the presence of dilated vessels (regardless of the size) in one of the five territories of porto-systems shunting, i.e. gasto-oesophageal, spleno-renal, para-umbilical or parietal, mesenteric or peri-rectal, and retroperitoneal. Discrimination with systemic-pulmonary shunts was made following the different pathways.
A combination of liver peripheral atrophy with hyper signal intensity on T2-weighted imaging and delayed enhancement (short 'periphery') and subcapsular intermingled enhanced septa (short 'reticulation') were scored on MRI. Apparent diffusion coefficient and relative enhancement ratio (RER) were calculated on diffusion-weighted imaging, as a modification of methodology described before (see Supplementary material online, Methods). 34 All focal liver lesions were described and when larger than 10 mm scored on the following characteristics: signal T1 and T2 intensity, diffusion-weighted intensity, intensity on different contrastenhanced phases, washout, fat content, capsule formation, and central scar. Alpha-fetoprotein (AFP) was measured in patients with focal liver lesions. 
Statistical analyses
Results
Clinical characteristics
A total of 49 patients with a Fontan physiology were referred for simultaneous cardiac and hepatological screening. Eleven patients refused biopsy, so they were excluded from further analyses. The cohort consisted of 38 patients, prospectively assessed with the multimodality approach (see Figure 1) . Mean age at time of screening was 27 ± 6.6 years, with 74% males. Average time after completion of the Take home figure Prospective multimodality assessment of Fontan-associated liver disease.
The clinical spectrum of Fontan-associated liver disease
Fontan circulation was 21.4 ± 5.5 years. For all characteristics (see Table 1 ).
Based on cardiac ultrasound assessment, 21 (55%) patients had good systolic function of the systemic ventricle, 15 (40%) patients had mild dysfunction, and 2 (5%) patients had moderate dysfunction. 23 The majority of patients were classified as New York Heart Association (NYHA) I (90%) or NYHA II (10%). All patients had regular physical activity, but the mean VO 2 max, as a marker of exercise tolerance, was 25.2 ± 5.8 mL/kg/min corresponding with 56 ± 12% of age and gender matched healthy individuals. 24 Patients had a median body mass index of 22.2 (20.3-24.6 ) kg/m 2 and a median alcohol consumption of 1 (0-4) units/week. None tested positive for hepatitis B or C. Physical examination of patients did not reveal any signs or symptoms suggestive for chronic liver disease. All, but one patient, were treated with anti-thrombotics. Eleven patients (29%) used platelet aggregation inhibitors, while 26/38 used oral anticoagulants (23/26 coumarin derivatives and 3/26 direct oral anti-coagulants).
Liver histology
All patients underwent percutaneous liver biopsy without any complications defined as severe pain, bleeding, or any cause that required prolonged admission, additional diagnostic procedures, or treatment. Antithrombotic or anticoagulant medication could be temporarily interrupted without bridging. No thrombotic events occurred.
All biopsies were of sufficient quality. There was substantial interobserver agreement on portal fibrosis score between both pathologists [kappa = 0.747, 95% confidence interval (CI) 0.615-0.879], but The median gross architectural distortion score was 3 (2-4). Median score for portal fibrosis was 2 (2-4) and for sinusoidal fibrosis 2 (1-2). Median CHFS was 3 (2.75-4). Eleven (29%) of patients had Stage 4; cirrhosis, on all three scores. There were no patients without fibrosis on any of the scores (Figure 2A) . Median sinusoidal dilatation was 1 (0.75-2) and median portal inflammation score was 0, with only three patients classified as mild to moderate inflammation (score 1-2). Steatosis was absent from all biopsies. Median CPA was 22.5% (16.9-29.5). Collagen proportionate area correlated with overall architectural distortion score (Rs = 0.457), portal fibrosis score (Rs = 0.524) and CHFS score (Rs = 0.419; all P < 0.01), but not with sinusoidal fibrosis score (Rs = 0.102, P = 0.541). Gross architectural score, portal fibrosis score, and CHFS all correlated significantly with each other (Rs > 0.800 and P < 0.001). Key histopathological features of FALD are depicted in Figure 2B .
For further analyses, patients were divided in two groups, based on stage of fibrosis by gross architectural distortion score: 16 (42%) patients had mild fibrosis (Stages 1-2) and 22 (68%) patients had severe fibrosis (Stages 3-4).
Non-invasive assessment of Fontanassociated liver disease
Liver biochemistry Liver biochemistry did not differ between patients with mild and severe fibrosis ( Table 2) . To highlight, the majority of patients in both groups had an elevated GGT (80% of patients with mild fibrosis vs. 86% of patients with severe fibrosis, P = 0.670).
Bilirubin was increased in 30% of patients (20% with mild fibrosis and 41% with severe fibrosis, P = 0.286). Platelets (10 9 /L) were within normal range in most cases (73% in both groups). MELD-XI scores were similar between groups and almost all within normal range. None of the parameters correlated with CPA (data not shown).
Serum fibrosis markers
Median ELF score was above the threshold of 7.7 Figure 3A) . 
fibrosis (see
Ultrasonography and elastography
Six patients with severe fibrosis (27%; five with cirrhosis and one with Stage 3 on gross architectural score) had a heterogeneous liver aspect of the parenchyma, compared with none with mild fibrosis (P = 0.030). Median CPA was also significantly higher in patients who had a heterogeneous aspect of the liver on ultrasound [35% (27-37) vs. 22% (17-24), P = 0.026].
Portal vein flow was similar between patients with mild and severe fibrosis (see Figure 3C) . Portal vein flow and spleen size showed a moderate correlation with CPA (Rs = -0.442, P = 0.005 and Rs = 0.452, P = 0.004, respectively). Ultrasound and Doppler flow parameters are shown in Table 3 .
Fibroscan was successful in 36/38 patients. Median liver stiffness was 22.5 28.9 ) kPa, P = 0.511, see Figure 3B ], and did not correlate with CPA (Rs = -0.015, P = 0.931). Liver stiffness did not correlate to histological grade of sinusoidal dilatation (Rs = -0.079, P = 0.648).
Advanced imaging Fibrosis
In 30/38 patients we performed an MRI, and eight patients were subjected to a CT-scan. Nodularity was a frequently observed feature, absent only in five patients and was evenly distributed between patients with mild and severe fibrosis. Other semi-quantitative fibrosis features were also equally present in patients with mild and severe fibrosis (see Table 4 ). The combination of specific hallmarks of cirrhosis; an enlarged caudate lobe, atrophied segment 4 and surface nodularity were present in five patients: two patients with severe fibrosis (Stage 3) and three patients with mild (Stage 2) fibrosis. Apparent diffusion coefficient and RER were similar between groups, and did not correlate with CPA (Rs = -0.092, P = 0.627 and Rs = -0.006, P = 0.972, respectively). None of the other histological component scores correlated with any of the imaging parameters (data not shown).
Assessment of portal hypertension
Varices were present in 19 (50%) patients, ascites in 22 (58%), and splenomegaly in 7 (18%) of patients. A combination of all three characteristics was found in five patients (see Table 5 ). Eight of 11 patients with cirrhosis (73%) had varices compared with 11/27 (41%) patients with a lower stage of fibrosis (P = 0.074). Collagen proportionate area was significantly higher in patients with varices than in patients without varices: median 24.2% (21.5-35.7) vs. 18 .5% (14.2-24.6), P = 0.015.
Liver stiffness was similar between patients with and without varices (mean 21.4 ± 11.3 kPa and 24.1 ± 9.1 kPa, P = 0.391, respectively). 
Hepatic nodules
Thirteen patients had several nodules smaller than 10 mm, while 13 had no nodules at all.
Nine patients had in total 25 focal hyperenhancing hepatic lesions larger than 10 mm (median 1 nodule per patient, ranging from 1 to 7) ( Table 6 ). The number of patients with nodules was comparable between patients with mild and severe fibrosis (n = 3, 19% and n = 6, 27%, P = 0.706, respectively) and patients with or without varices (four vs. five patients, P = 1.000). Patients with severe fibrosis did have more nodules (median 4 nodules; range 1-7) than patients with mild fibrosis (all three patients had one nodule, P = 0.047). Delayed-phase washout was present in nine nodules (36%) in five patients; one patient with cirrhosis ( None of these nodules had additional ancillary features such as hyperintensity on T2 and DWI images or fat content. The mean AFP was low in all patients (mean AFP 3.39 ± 1.29 lg/L).
Discussion Key findings
This study demonstrates (i) the presence of severe liver fibrosis, signs of portal hypertension, and hyperenhancing nodules in a majority of asymptomatic patients with a Fontan physiology and (ii) the lack of correlation between several non-invasive diagnostic tools and histological confirmed liver fibrosis severity. These findings indicate that non-invasive diagnosis of/screening for severe FALD in patients with a Fontan physiology is ineffective to accurately assess liver fibrosis.
Screening of Fontan-associated liver disease
There is an unmet need to diagnose and assess liver fibrosis severity with non-invasive alternatives, as liver biopsy carries potential complications. Our data suggests that there is no role in clinical practice for ELF V R , routine transient elastography, or conventional MRI/CT to diagnose liver fibrosis in Fontan physiology, since it fails to correlate with histological fibrosis severity. Ultrasound abnormalities, such as heterogeneous aspect of parenchyma could be indicative for severe fibrosis, but absence of abnormalities does not rule out severe FALD. [35] [36] [37] This highlights that experiences from patients with other forms of liver disease (e.g. liver cirrhosis as a result of alcohol abuse, hepatitis B and C) cannot be applied to the Fontan population, as interference of congestion remains an issue of concern in this unique physiology.
35-37
Although we encountered no complications from the biopsy itself or from interruption of anticoagulant therapy, we acknowledge that liver biopsy is not an attractive tool to use for follow-up. Thus there remains an unmet need for alternatives to ease screening and followup in this population. MRI is subject to fast and major developments, and techniques such as T1-rho mapping, extracellular volume .. .......................................................................................... should be validated against histology before they are adopted in daily practice.
Pathophysiology
Although not fully elucidated, chronic passive hepatic congestion is thought to be the underlying mechanism that puts patients with a
Fontan physiology at risk for complications of advanced liver disease. 41 In congestive hepatopathy, venous congestion elicits a sustained wound-healing response. Upon histological examination, this is characteristically depicted by sinusoidal dilatation, presumably resulting from venous pressure elevation. Consequently fibrosis arises, with also mainly a sinusoidal pattern. 42 Over time, injury precipitates formation of broad scars, bridging fibrosis and cirrhosis. Fibrosis is also generated by microthrombotic events in sinusoids and veins. 43 The ubiquitous presence of fibrosis in all biopsies examined in this study, underlines the profound impact of the Fontan physiology on the liver architecture, and contrasts with that in other aetiologies such as viral hepatitis, where only a minority of patients will ultimately develop liver fibrosis. 44 The specific histological pattern of sinusoidal fibrosis in combination with sinusoidal dilatation can help to distinguish FALD from other liver diseases, however, correlation with clinical information should always be made to identify the definite cause of liver injury, as no pattern is unique in liver pathology. 45 The spectrum of Fontan-associated liver disease
The findings from our study are consistent with the spectrum of FALD ranging from mild congestive hepatopathy to established cirrhosis. At 21 years after surgery, the majority of patients have developed advanced liver disease. Some 29% had histological evidence of liver cirrhosis and 50% had varices. These findings are in line with those from other Fontan cohorts, reinforcing the concept that liver fibrosis and portal hypertension are major extra-cardiac manifestations of Fontan physiology. 17, 19, 46, 47 This reflects the ongoing continuum that starts post-operatively with hepatic vein congestion, which causes liver injury resulting in ongoing fibrogenesis. 5 To address the true risk of advanced liver disease and its complications in patients with a Fontan physiology we need longitudinal data that associate presence and severity of FALD to morbidity and mortality. 16, 48, 49 In other chronic liver diseases, such as viral hepatitis and NAFLD, fibrosis stage determines portal hypertensive complications hepatocellular carcinoma (HCC) development and ultimately prognosis. 50 If this is also the case in patients with a Fontan physiology needs to be further elucidated by prospective studies.
Portal hypertension
In our cohort, signs of portal hypertension were more frequently seen in patients with cirrhosis. Splenomegaly and portosystemic varices are uncommon in congestive hepatopathy and are generally related to central venous pressure being transmitted through dilated hepatic sinusoids to the portal venous system. We did not perform measurements of the transhepatic pressure gradient, but in congestive hepatopathy and FALD values are usually normal. 41, 42 The presence of varices may be an indication of the transformation from congestion to fibrosis. 51 To what degree failure of Fontan physiology contributes to the onset of portal hypertension remains unknown.
Fontan nodules
Congestive hepatopathy is also associated with the onset of focal liver lesions. Arterialized large regenerative nodules or focal nodular The clinical spectrum of Fontan-associated liver disease hyperplasia (FNH) are often found in congestive hepatopathy. 52, 53 These lesions comprise of regions of parenchyma with compromised hepatic venous outflow and subsequently impaired portal inflow. Parenchymal perfusion thus becomes reliant on arterial flow, resulting in nodular regeneration of hepatocytes. It is generally assumed that FNH have no malignant potential. 54 On the other hand, cirrhosis is associated with an increased risk of HCC, and HCC has been described in young cirrhotic patients with a Fontan physiology. 55, 56 Hyperenhancing nodules were present in approximately 25% of patients from our cohort, independent of fibrosis stage, corroborating previous findings. 53, 57 Wash-out, in the setting of cirrhosis, is usually a specific feature of HCC, but in FALD may also be present in benign lesions. 53 Specific guidelines for screening of patients with a Fontan physiology for HCC are lacking, 58 but the value of AFP, liver-specific contrast agents, and additional ancillary features for discrimination between benign and potentially malignant Fontan nodules should be further explored.
Liver function and transplantation
Finally, liver function is an issue of concern. Liver function is defined as the ability to maintain bilirubin metabolism and intact coagulation, and not as the increase of transaminotransferases. 59 Liver fibrosis is an important prognostic determinant in patients with other chronic liver diseases as it may result in impaired liver function and increased mortality. 50 It is suggested that 5-year survival in cirrhotic patients with Fontan physiology was dismal which in turn was due to both cardiac and liver related complications. 15 Clinical follow-up of patients with established liver disease is facilitated by the MELD (Model of End stage Liver Disease) score, prioritizing patients in need of liver transplantation. 60 Transplantation data are very limited and come from several small case series that describe combined heart and liver transplantation in patients with a failing Fontan physiology and liver cirrhosis. [61] [62] [63] These show good short term results, comparable to orthotopic heart transplant. Nonetheless, long-term results are lacking. In adjusted form, MELD-XI probably predicts cardiac mortality or heart transplantation better than hepatological mortality, as similar outcomes are observed regardless of the presence of severe fibrosis. 64 In our cohort, MELD-XI scores were low.
Strengths and limitations
The major strength of our study lies in the optimal identification of fibrosis in this population using a gold standard: histological confirmation. This allows us to interpret the observations as a result of either congestion, fibrosis or combined. The use of multiple invasive and non-invasive modalities for the same patients allows a fine comparison of the diagnostic value to detect congestion or fibrosis in relation to the gold standard. Previous studies investigating non-invasive alternatives to assess FALD lacked reference to the gold standard, hampering interpretation of results. Selection bias was limited since every consecutive patient was included and subjected to structural assessment. Liver fibrosis severity in our cohort is probably representative for the general population with Fontan physiology. Therefore, we can answer to several important key knowledge gaps as identified by the stakeholders meeting of the American College of Cardiology in 2017. 65 Our study is limited by the relatively small number of patients, but on the other hand our cohort underwent systematic and deep characterisation of the phenotype. The study design is cross-sectional, and exposure and outcome were simultaneously assessed. Without the presence of longitudinal data it is not possible to establish temporal relation between cause (Fontan physiology) and effect (liver fibrosis and its complications) or to assess the value of non-invasive diagnostics in monitoring of FALD. Longitudinal assessment of liver stiffness measurements has the potential to be helpful in monitoring patients with a Fontan physiology, 40 but needs further confirmation.
Future research should focus on assessing modalities for surveillance of these patients and on pathophysiology and risk factors for progression of FALD. 65 
Conclusion
In conclusion, we show that cirrhosis and signs of portal hypertension are present in substantial proportion of patients with a Fontan physiology, and that MRI, CT, transient elastography, and serum biomakers are unable to accurately assess severity of liver fibrosis in this cohort. This emphasizes the need for prospective longitudinal follow-up studies to further assess morbidity and mortality risk and to search for non-invasive alternatives to diagnose and monitor FALD.
